Genetics
Patients With Breast Cancer and BRCA1, BRCA2, CHEK2, or PALB2 Germline Pathogenic Variants May Benefit From Enhanced Surveillance
January 25, 2023
Article
Patients with breast cancer who carry BRCA1, BRCA2, CHEK2, or PALB2 germline pathogenic variants may be at a greater risk for contralateral breast cancer and may benefit from enhanced surveillance and risk-reduction strategies.
Retrospective MOUNTAINEER Analysis Sheds Light on Optimal HER2 Testing Practices in mCRC
January 23, 2023
Article
Both the gastric and breast cancer HER2 scoring algorithms may be useful in determining which patients with metastatic colorectal cancer may derive benefit with tucatinib/ trastuzumab.
Novel Intervention Reduces Time to Molecular Testing for Patients With NSCLC In Community Practice Setting
November 07, 2022
Article
A quality improvement project improved the time to molecular testing for patients with newly diagnosed, metastatic non–small cell lung cancer.
Derazantinib Shows PFS Efficacy in FGFR2+ Intrahepatic Cholangiocarcinoma
October 08, 2022
Article
Derazantinib, an FGFR inhibitor, was associated with a median progression-free survival (PFS) of 7.8 months in patients with FGFR2-positive intrahepatic cholangiocarcinoma.
Rucaparib Boosts Radiographic Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer
October 07, 2022
Article
The median radiographic progression-free survival (rPFS) was 11.2 months among patients with castration-resistant prostate cancer who received rucaparib. In the control arm, median rPFS was 6.4 months.
Daly Discusses Biomarkers and Emerging Targeted Therapies for Cancer Care
September 20, 2022
Article
Kristin Daly, MSN, ANP-BC, AOCNP, discusses the clinical significance of tumor variants and how they are changing the direction of cancer care.
Podsada Discusses Biomarker Testing and ADC Therapies in Breast Cancer
August 16, 2022
Article
The growing availability of biomarkers has led to the advent of more targeted therapies such as the antibody-drug conjugates (ADCs) fam-trastuzumab deruxtecan-nxki, ado-trastuzumab emtansine, and sacituzumab govitecan-hziy.
HER2-Directed Therapy, Trastuzumab Deruxtecan, Approved for Metastatic NSCLC
August 12, 2022
Article
The FDA has approved trastuzumab deruxtecan for patients with HER2-mutated non–small cell lung cancer after the DESTINY-Lung02 results demonstrated a 57% overall response rate with the agent. The drug comes with warning for interstitial lung disease, neutropenia, and left ventricular dysfunction.
Capmatinib Snags Full FDA Approval for MET Exon 14 Skipping NSCLC
August 11, 2022
Article
The FDA has granted capmatinib regular approval for patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have a mutation leading to MET exon 14 skipping. The drug comes with warning for pneumonitis, hepatotoxicity, and pancreatic toxicity.
Beth Sandy on Incorporating Amivantamab and Mobocertinib into Clinical Practice for Patients With EGFR Exon 20 Insertion NSCLC
August 05, 2022
Video
Beth Sandy, MSN, CRNP, discusses the application of 2 FDA approved drugs for patients with non–small cell lung cancer and an exon 20 insertion mutation.